Last reviewed · How we verify

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

NCT00637000 Phase 2 COMPLETED Results posted

The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate an opioid withdrawal syndrome.

Details

Lead sponsorIndivior Inc.
PhasePhase 2
StatusCOMPLETED
Enrolment38
Start date2008-03
Completion2008-09

Conditions

Interventions

Primary outcomes

Countries

United States